Patents by Inventor Yen Lin CHIA

Yen Lin CHIA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-IFNAR1 DOSING REGIME FOR SUBCUTANEOUS INJECTION
    Publication number: 20230365698
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 21, 2023
    Publication date: November 16, 2023
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Sr., Joachim ALMQUIST, Thomas ROUSE
  • TREATMENT OF LUPUS NEPHRITIS
    Publication number: 20220348669
    Abstract: The disclosure relates to methods and compositions for the treatment of lupus nephritis. Specifically, the disclosure relates to methods comprising administering to a subject a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 22, 2022
    Publication date: November 3, 2022
    Applicant: AstraZeneca AB
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE, Teodora TRASIEVA, Wendy WHITE, Dominic SINIBALDI, Madhu RAMASWAMY, Paul NEWCOMBE
  • DOSE
    Publication number: 20220340669
    Abstract: The disclosure relates to methods and compositions for the treatment of type I IFN mediated disease. Specifically, the disclosure relates to a subcutaneous dose of a type I IFN receptor inhibitor.
    Type: Application
    Filed: April 22, 2022
    Publication date: October 27, 2022
    Applicant: AstraZeneca AB
    Inventors: Catharina LINDHOLM, Yen Lin CHIA, Rajendra TUMMALA, Lorin ROSKOS, Joachim ALMQUIST, Tomas ROUSE
  • Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor
    Publication number: 20190049450
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor, and correlating the level of one or more tumor markers in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Application
    Filed: October 3, 2018
    Publication date: February 14, 2019
    Inventors: Yen Lin Chia, Ute Hoch, Alison Hannah, Michael A. Eldon
  • Method for assessing and predicting efficacy of breast cancer treatment with a long-acting topoisomerase I inhibitor
    Patent number: 10132810
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: November 20, 2018
    Assignee: Nektar Therapeutics
    Inventors: Yen Lin Chia, Ute Hoch, Alison Hannah, Michael A. Eldon
  • Method for Assessing and Predicting Efficacy of Breast Cancer Treatment with a Long-Acting Topoisomerase I Inhibitor
    Publication number: 20150309032
    Abstract: Provided is a method of treating an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor such as SN-38 or irinotecan, and correlating the level of at least one tumor marker such as CA27.29 in the individual with response of the cancer to treatment with the long-acting topoisomerase I inhibitor, to thereby provide a method for predicting and assessing the therapeutic efficacy of the treatment.
    Type: Application
    Filed: November 27, 2013
    Publication date: October 29, 2015
    Applicant: NEKTAR THERAPEUTICS
    Inventors: Yen Lin CHIA, Ute HOCH, Alison HANNAH, Michael A. ELDON